Management will detail Coherus’ strategy to build an innovative immuno-oncology franchise funded with a diversified portfolio of FDA-approved therapeutics.

Additionally, Coherus will provide updates on preparation for multiple new product launches anticipated in the next 15 months, the Company’s transformational entry into immuno-oncology with PD-1 inhibitor toripalimab, and the advancement of innovative PD-1 combination candidates.